Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.30 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8133589 | 0.79 | L3MBTL1 (0.39) | TSHR | |
| SCHEMBL129417 | 0.76 | — | — | |
| SCHEMBL129210 | 0.73 | GABRP (0.36) | MCHR1 | |
| SCHEMBL1810241 | 0.73 | ALDH1A1 (0.41) | — | |
| SCHEMBL14771962 | 0.73 | TSHR (0.48) | MCHR1TSHR | |
| SCHEMBL6543436 | 0.72 | TRPV3 (0.31) | — | |
| SCHEMBL128336 | 0.71 | LTA4H (0.39) | MCHR1TSHR | |
| SCHEMBL2352311 | 0.71 | TSHR (0.38) | TSHR | |
| SCHEMBL443347 | 0.71 | BTK (0.39) | TSHR | |
| SCHEMBL6544830 | 0.70 | ALDH1A1 (0.42) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | claimed |
| US-8962835-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2015-02-24 | — | — | US | claimed |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-11-21 | — | — | US | claimed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | claimed |
| US-8440667-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-05-14 | — | — | US | claimed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | claimed |
| EP-3552607-A2 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-2373318-B1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2019-06-05 | — | — | EP | disclosed |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2017-05-04 | — | — | US | disclosed |
| US-9567348-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2015-09-24 | — | — | US | disclosed |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-8440667-B2 | Imidazopyrazine Syk inhibitors | GILEAD CONNECTICUT, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2373318-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-06-17 | — | — | US | disclosed |
| WO-2010068258-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266902-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | IL1B 1013/4885NUDT1 2684/4885MCHR1 4116/4885 |
| US-10093684-B2 | Substituted imidazo[1,2-a]pyrazines as Syk inhibitors | SYK, BTK, ZAP70 | IL1B 405/4885NUDT1 3627/4885MCHR1 3325/4885 |
| US-20130310363-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, BTK, ZAP70 | IL1B 529/4885NUDT1 3656/4885MCHR1 4157/4885 |
| US-20130231330-A1 | IMIDAZOPYRIZINE SYK INHIBITORS | SYK, ZAP70, BTK | IL1B 921/4885NUDT1 3139/4885MCHR1 4393/4885 |
| US-20170121350-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | IL1B 1013/4885NUDT1 2684/4885MCHR1 4116/4885 |
| US-20100152159-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | IL1B 1013/4885NUDT1 2684/4885MCHR1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.